MEKanistic Therapeutics

MEKanistic Therapeutics is a biotechnology company dedicated to developing innovative kinase inhibitors for cancer treatment. The company's lead candidate is a rationally designed drug capable of blocking two key pathways (EGFR and PI3K) of cancer cell growth with a single molecule. Preclinical studies of its lead drug, MTX-531, have shown a high rate of tumor regression with significantly reduced toxicity.